Lite Strategy

Lite Strategy Capital Intensity

The Capital Intensity Ratio of Lite Strategy (LITS) as of Nov 20, 2026 is 63.36 %. In the previous year, Capital Intensity Ratio was 247.48 % — a change of -74.40% (lower).

Capital Intensity

63.36 %

YoY

-74.40%

Last updated:

Capital Intensity Ratio of Lite Strategy is 2024 63.36 % . Capital Intensity Ratio of Lite Strategy was 2023 247.48 % . It decreases by -74.40% lower compared to the previous year.

The Lite Strategy Capital Intensity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Capital Intensity
Date
Capital Intensity
Jan 1, 2017
239.57 USD
Jan 1, 2018
6,462.96 USD
Jan 1, 2019
1,680.89 USD
Jan 1, 2020
755.40 USD
Jan 1, 2021
500.34 USD
Jan 1, 2022
436.99 USD
Jan 1, 2023
247.48 USD
Jan 1, 2024
63.36 USD
The Lite Strategy Capital Intensity history
YEARCapital IntensityYoY
63.36 %-74.40%
247.48 %-43.37%
436.99 %-12.66%
500.34 %-33.77%
755.40 %-55.06%
1,680.89 %-73.99%
6,462.96 %+2,597.74%
239.57 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Lite Strategy Stock analysis

What does Lite Strategy do? MEI Pharma, Inc. develops cancer therapies, focusing on clinical drug candidates including Pracinostat, ME-344, and ME-401. Pracinostat, an HDAC inhibitor for hematologic diseases like AML and MDS, has undergone Phase I and II trials. ME-344 targets mitochondrial components in rapidly proliferating cells, while ME-401 inhibits PI3K delta for hematologic cancer treatment. The company generates revenue through clinical development and potential future drug sales, targeting oncology markets with its pipeline of cancer therapies. The firm's products are developed for specific cancer indications, with Pracinostat tested in advanced hematologic malignancies and solid tumors. ME-344 and ME-401 address unmet needs in mitochondrial and PI3K delta pathways, respectively. MEI Pharma's revenue model relies on clinical trial progress and future commercialization of these therapies, aiming to secure partnerships or direct sales in oncology. MEI Pharma's portfolio includes three clinical drug candidates, each targeting distinct cancer mechanisms. Pracinostat is advanced in trials for AML and MDS, while ME-344 and ME-401 are in development for broader cancer applications. The company monetizes through potential drug approvals and sales, with a focus on hematologic cancers and solid tumor markets. Lite Strategy is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Lite Strategy stock

Capital Intensity Ratio of Lite Strategy is 63.36 % in 2024.

Capital Intensity Ratio of Lite Strategy changed from 247.48 % to 63.36 %, representing a -74.40% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Capital Intensity Ratio Lite Strategy since 2006 – with annual values, charts, and detailed analysis.

Capital intensity measures the amount of assets needed to generate each unit of revenue. Lower ratios indicate asset-light business models.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Capital Intensity Ratio's Lite Strategy with sector peers and the industry average to assess whether it is attractive.

To evaluate Capital Intensity Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Capital Intensity Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Lite Strategy

All Key Metrics — Lite Strategy